{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:28:21Z","timestamp":1777955301562,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Serum soluble B-cell maturation antigen (sBCMA) has been shown to correspond to high disease burden in uncontrolled Multiple Myeloma (MM). However, it has not been extensively evaluated as a biomarker of minimal\/measurable residual disease (MRD). <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective observational correlative study, the primary objective was to correlate serum sBCMA with tumor burden in the bone marrow (BM) of patients with MM evaluated for first or salvage autologous stem cell transplantation. Paired samples were collected from 44 patients. BM overt disease was identified on morphological analysis or by standard flow cytometry (limit of detection (LOD) of 10-1). BM MRD was assessed by MRD flow cytometry (sensitivity of 1 aberrant clonal plasma cell in 10<jats:sup>5<\/jats:sup> nucleated cells) and\/or next-generation sequencing (LOD of 10-6). <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For transplant recipients (n= 36), the mean serum sBCMA (standard deviation (SD)) was 18.1 (11.7) ng\/mL, BM overt disease was present in 12 (33.3%) patients and MRD only\/No MRD in 20 (55.6%) patients. For non-transplanted patients (n= 8), the mean serum sBCMA was 9.7 (5.2) ng\/mL, BM overt disease was present in 1 (12.5%) patient, while MRD only\/No MRD in 5 (62.5%) patients. Serum sBCMA was associated with overt disease (p &amp;lt; 0.001), as well as MRD only\/No MRD (p= 0.002). On multivariable logistic regressions modeling, higher serum sBCMA indicated higher odds of BM overt disease (odds ratio (OR) = 1.12, p = 0.007) and lower odds of MRD only\/No MRD (OR = 0.91, p = 0.03). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum sBCMA was associated not only with BM overt disease, but also with BM detectable or below LOD MRD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1631511","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:18:26Z","timestamp":1757391506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Soluble B-cell maturation antigen as a serum marker of MRD in patients with multiple myeloma"],"prefix":"10.3389","volume":"15","author":[{"given":"Erin A.","family":"Dean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith M.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack W.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Hiemenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: past, present, and future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.161414","article-title":"Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"B8","unstructured":"Human BCMA\/TNFRSF17 DuoSet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4509","article-title":"Classification accuracy and cut point\u2009selection","volume":"31","author":"Liu","year":"2012","journal-title":"Stat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e25151","DOI":"10.1002\/jcla.25151","article-title":"Predictive role of soluble B-cell maturation antigen in short-term monitoring of differently treated multiple myeloma patients: A prospective study","volume":"39","author":"Caponi","year":"2025","journal-title":"J Clin Lab Anal"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026028","article-title":"Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma","volume":"145","author":"Ikeda","year":"2025","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01624-5","article-title":"P-006 SBCMA has utility for early response monitoring in the blood and is correlated with forimtamig pharmacodynamic activity, clinical response and MRD","volume":"23","author":"Dekhtiarenko","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S2152-2650(23)01623-3","article-title":"P-005 Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"23","author":"Boyapati","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110574","article-title":"The role of signaling lymphocytic activation molecule (SLAM) family receptors in health and disease progression: Focusing on cancer and therapy","volume":"26","author":"Luo","year":"2025","journal-title":"Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0356","article-title":"CIC mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement","volume":"25","author":"Vi\u00e0","year":"2020","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1631511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:18:28Z","timestamp":1757391508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1631511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1631511"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1631511","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"article-number":"1631511"}}